<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90650">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817153</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2012-04</org_study_id>
    <secondary_id>2012-004736-39</secondary_id>
    <nct_id>NCT01817153</nct_id>
  </id_info>
  <brief_title>Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.</brief_title>
  <acronym>HyStOON</acronym>
  <official_title>Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of the study are 1)to examine the immediate (2 hours) and delayed (8
      hours) effects of intravenous hydrocortison on macro and microvascular post-ischemic
      vasoreactivity, in septic shock adult patients; 2) to examine possible correlations between
      post-ischemic flow-mediated dilation (FMD) of the brachial artery (assessed by ultrasound
      imaging) and post-ischemic recovery slope of the thenar oxygen saturation (StO2) (assessed
      by near-infrared spectroscopy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two primary end points, considered as reflecting vasoreactivity will be assessed :

        1. Flow-mediated dilation (FMD) of the brachial artery, measured by ultrasound imaging,
           expressed in mm or in percentage, will be calculated from artery diameters measured
           before and after a vascular occlusion test (cuff around arm or forearm).

        2. recovery slope of thenar oxygen saturation (StO2), assessed by near infrared
           spectroscopy (NIRS), expressed in %/second, will be recorded after the vascular
           occlusion test.

      The two primary end points (FMD and recovery slope of StO2)will be assessed at the following
      timepoints :

        -  baseline (before first injection of placebo or hydrocortison)

        -  2 hours after first injection of placebo or hydrocortison

        -  2 hours after second injection of placebo or hydrocortison (i.e. 8 hours after first
           injection)

        -  4 to 6 hours after third injection

        -  4 to 6 hours after fourth injection (optional)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Vasoreactivity</measure>
    <time_frame>every 6 hours over the first 24 hours of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Septic Shock</condition>
  <condition>Adult</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hydrocortison</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortison hemisuccinate</intervention_name>
    <arm_group_label>hydrocortison</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo followed by hydrocortisone hemisuccinate</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 yrs

          -  consent obtained

          -  septic shock (according to international definition)

          -  patient sedated and submitted to invasive mechanical ventilation

          -  no need for surgery expected within 24 hours after enrollment

          -  patient has received at least one dose of large spectrum antibiotics

          -  superior vena cava catheter in place

          -  patient carrying a thermodilution device for cardiac output measurement

          -  stable mean arterial pressure within 65-5 mmHg limits for at least 2 hours;

        Exclusion Criteria:

          -  pregnancy

          -  age below 18 years

          -  patient treated with iv continuous epinephrine

          -  chronic occlusive arteriopathy of the upper limbs

          -  regular or recent treatment with glibenclamide or glipizide

          -  regular or recent treatment with steroids

          -  known surrenal insufficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Boulain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Régional d'Orléans, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry Boulain, MD</last_name>
    <email>thierry.boulain@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johann Le Drogoff</last_name>
    <email>johann.le-drogoff@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Boulain, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Johann Le Drogoff</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thierry Boulain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 17, 2013</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Régional d'Orléans</investigator_affiliation>
    <investigator_full_name>Thierry BOULAIN</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone-17-butyrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
